Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 416970 in Healthy Male Volunteers in a Partially Randomised, Single-blind, Placebo-controlled Trial, Investigation of Relative Bioavailability of BI 416970 (Open-label, Randomised, Three-way Cross-over) and Assessment of Safety and Exposure of BI 416970 in CYP2C9 Genotyped Volunteers (Open-label, Single-dose)
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2016
At a glance
- Drugs BI 416970 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 09 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 10 Jun 2014 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
- 28 Mar 2014 New trial record